Article Per Year (5 Year)
p-Index From 2020 - 2025
1.503
P-Index
This Author published in this journals
All Journal Farmasains : Jurnal Farmasi dan Ilmu Kesehatan Pharmascience Qanun Medika - Medical Journal Faculty of Medicine Muhammadiyah Surabaya Manuju : Malahayati Nursing Journal Jurnal Ilmiah Ibnu Sina (JIIS): Ilmu Farmasi dan Kesehatan Indonesian Journal of Biomedicine and Clinical Sciences Jurnal Sains dan Kesehatan
Fauna Herawati
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Nursing Public Health

Published : 7 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 7 Documents
Search

 1 
Influence of historical use of antibiotics toward antibiotic resistance Fawandi Fuad Alkindi; Rika Yulia; Fauna Herawati; Abdul Kadir Jaelani
Farmasains : Jurnal Farmasi dan Ilmu Kesehatan Vol. 4 No. 1 (2019)
Publisher : Universitas Muhammadiyah Malang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22219/farmasains.v4i1.7901

Abstract

A WHO’s Global Surveillance of Antibiotic Resistance showed there is an increase of antimicrobial resistance in Asia between 2013 until 2014. Many studies showed that there is a correlation between prior antibiotic use with antimicrobial resistance case. The primary objective of this study is to analyze the relationship between prior antibiotic use with antimicrobial resistance. İt was a retrospective and descriptive study conducted at Bangil Regional General Hospital. The data collected from the medical record and microbiological test from the patient at the internal ward. Chi-square analysis used for the statistic. This study showed that prior antibiotic use increased 0,399 bigger for antimicrobial resistance rate (p=0,001). 
Roflumilast: A Review of Chronic Obstructive Pulmonary Disease (COPD) Treatment Ita Octafia; Dwi Octamy Sari; Novi Wulandari; Sandra Annisa; Linda Wahyuni Wongkar; Ferdias Kurnia Bahari; Faiz Farikhah; Moh Firmansah; Erfin Midhiawati; Fauna Herawati
Qanun Medika - Jurnal Kedokteran FK UMSurabaya Vol 5, No 1 (2021)
Publisher : Universitas Muhammadiyah Surabaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30651/jqm.v5i1.5043

Abstract

Abstract Chronic Obstructive Pulmonary Disease (COPD) is a chronic airway inflammation with resulting progressive airflow limitation that has a high incidence, morbidity, and mortality. Roflumilast is an oral phosphodiesterase-4 inhibitor as a therapy to decrease the risk of COPD exacerbations in patients with moderate-severe COPD with a history of chronic bronchitis. Roflumilast can be given orally once daily as a single or combination drug. It can be used as COPD moderate-severe but also more beneficial as COPD mild treatment. The efficacy of Roflumilast can prevent exacerbations of repetition and can fixed lung function both in terms of FEV1 and vital capacity to force. The incidence of side effects, which are diarrhea and digestive disorders. The cost-effectiveness showed that Quality of life patient with Roflumilast is better than the group without additional. This paper aimed to review systematically Roflumilast as COPD treatment for the clinical application.Keywords                   : COPD, Roflumilast, phosphodiesterase-4 inhibitorCorrespondence          : fauna@staff.ubaya.ac.id
Evaluasi Penggunaan Antibiotik pada Pasien Bedah Bersih Terkontaminasi di Rumah Sakit Bhayangkara Surabaya Nurul Akhirin Nisak; Rika Yulia; Ruddy Hartono; Fauna Herawati
Jurnal Pharmascience Vol 9, No 1 (2022): Jurnal Pharmascience
Publisher : Program Studi Farmasi FMIPA Universitas Lambung Mangkurat

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20527/jps.v9i1.10107

Abstract

Bedah bersih terkontaminasi merupakan prosedur bedah yang dilakukan pada traktus bilier, traktus urinarius, respiratorius dan digestif, reproduksi kecuali ovarium atapun operasi tanpa disertai kontaminasi yang nyata. Bedah bersih terkontaminasi memiliki potensi terjadinya infeksi sebesar 3-11% untuk mencegah dan mengatasi terjadinya infeksi diperlukan pemberian antibiotik. Penelitian ini bertujuan untuk mengevaluasi penggunaan antibiotik dalam satuan Defined Daily Dose (DDD)/100 patient-days pada pasien bedah bersih terkontaminasi di RS Bhayangkara Surabaya. Metode penelitian dilakukan secara retrospektif observasional pada pasien rawat inap bedah dalam periode 1 Januari-31 Desember 2020. Hasil penelitian didapatkan 40 data medis kesehatan pasien yang memenuhi kriteria inklusi dan eksklusi. Total nilai DDD/100 patient-days antibiotik profilaksis tertinggi adalah ceftriaxone 25 DDD/100 patient-days, sedangkan antibiotik terapi yang paling tinggi adalah amoxicillin 38,35 DDD/100 patient-days. Antibiotik yang termasuk dalam segmen DU 90% pada penggunaan antibiotik profilaksis adalah ceftriaxone, cefazolin, dan amoxicillin; sedangkan untuk antibiotik terapi adalah amoxicillin, ceftriaxone, metronidazole, dan cefadroxil. Kesimpulan dari penelitian ini adalah penggunaan antibiotik pada bedah bersih terkontaminasi tinggi dan jenis antibiotik yang paling banyak digunakan adalah antibiotik golongan sefalosporin generasi 3 (ceftriaxone) yang spektrum antibakterinya lebih luas daripada antibiotik golongan sefalosporin generasi 2 (cefazolin).Kata Kunci: DDD/100 patient-days, Bedah Bersih Terkontaminasi, AntibiotikClean-contaminated surgery is a surgical procedure performed on the biliary tract, urinary tract, respiratory and digestive tracts, reproduction except for the ovaries or surgery with no contamination encountered. This procedure has a potential infection in the range of 3-11%, therefore it is necessary to give antibiotics to prevent and treat the possibility of infections. This study was to evaluate the use of antibiotics using the Defined Daily Dose (DDD)/100 patient-days in clean-contaminated surgical patients at Bhayangkara Hospital Surabaya. Data was collected retrospectively observational in surgical inpatients from 1st January-31st December 2020. Total samples 40 met the inclusion and exclusion criteria. The highest total DDD prophylactic antibiotic value was ceftriaxone 25 DDD/100 patient-days. On the other hand, the highest therapeutic antibiotic was amoxicillin 38.35 DDD/100 patient-days. The antibiotics included in the 90% DU segment in the use of prophylactic antibiotics were ceftriaxone, cefazolin, and amoxicillin. Meanwhile, for therapeutic antibiotics, namely amoxicillin, ceftriaxone, metronidazole, and cefadroxil. The use of antibiotics in clean surgery is high and the type of antibiotic that is most widely used is the third generation cephalosporin antibiotic (ceftriaxone) whose antibacterial spectrum is wider than the second generation cephalosporin antibiotic (cefazolin).
Profil Penggunaan Obat pada Pasien Covid -19 di Ruang Isolasi Rumah Sakit X Kabupaten Malang Retno Juwita Sari; Rika Yulia; Fauna Herawati
Malahayati Nursing Journal Vol 4, No 11 (2022): Volume 4 Nomor 11 2022
Publisher : Universitas Malahayati Lampung

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33024/mnj.v4i11.7169

Abstract

ABSTRACT Respiratory tract infections in early 2020 increased drastically due to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Up to this point, therapy for this infection is referring to SARS-CoV-1 and MERS-CoV infections. Implementing secure and effective treatment for COVID-19 is indispensable. Drug repurposing/ drug reuse is a process to identify new indications of existing drugs. WHO recommends to optimize supportive care to support the main therapy in treating COVID-19.Objective of the study is to describe drug usage during COVID-19 pandemic. This study is observational, on adult subjects with confirmed COVID-19, with moderate to severe level of disease, data of whom was collected retrospectively during the period of April – March 2021. The findings reported 212 patients were treated as sample of the study, most of whom were male (50.9%). The highest age group was 56 – 65 years old by 27.4%. Frequent clinical symptoms were cough and shortness of breath; the highest profile of drug usage was supplement; and outcome for discharge improvement by 85.3%. Keywords: COVID-19, Drug Profile, Hospitalization, Outcome  ABSTRAK Kasus infeksi saluran pernafasan awal tahun 2020 meningkat secara drastis disebabkan oleh virus  Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Hinggga saat ini terapi yang digunakan mengacu dari pengobatan infeksi SARS-CoV-1 dan MERS-CoV. Kebutuhan pengobatan COVID-19 yang aman serta efektif sangatlah penting. Drug repurposing/ penggunaan obat kembali merupakan proses untuk mengidentifikasi indikaasi baru dari obat yang telah ada. WHO merekomendasikan perawatan suportif tetap dioptimalkan untuk menunjang terapi utama dalam pengobatan COVID-19. Penelitian ini bertujuan untuk mendiskripsikan penggunaan obat dimasa pandemik COVID-19. Penelitian ini merupakan penelitian observasional dengan pendekatan secara cross sectional,pada subyek dewasa yang terkonfirmasi COVID-19 derajat penyakit sedang hingga berat dengan pengambilan data penelitian secara retrospektif selama periode April 2020 – Maret 2021. Hasil menunjukkan terdapat sampel penelitian sebanyak 212 pasien yang terbanyak laki-laki (50,9%).. Penelitian ini bertujuan mendiskripsikan profil penggunaan obat dimasa pandemik COVID-19. Penelitian ini merupakan penelitian observasional pada subyek dewasa yang terkonfirmasi COVID-19 derajat penyakit sedang hingga berat dengan pengambilan data penelitian secara retrospektif selama periode April 2020 – Maret 2021. Hasil menunjukkan terdapat sampel penelitian sebanyak 212 pasien yang terbanyak laki-laki (50,9%). Rentang usia tertinggi pada usia 56 – 65 tahun sebesar 27,4%. Gejala klinis yang sering timbul adalah batuk dan sesak, profil penggunaan obat terbanyak yaitu suplemen serta outcome pulang perbaikan sebesar 85,3%. Kata Kunci: COVID-19, Profil Obat, Rawat Inap, Outcome
Efikasi dan Keamanan dari Pancreatic Enzyme Replacement Therapy pada Pasien Cystic Fibrosis : Sebuah Kajian Sistematis: Efficacy and Safety of Pancreatic Replacement Therapy (PERT) for patient with Cystic Fibrosis: A Systematic Review Ni Made Suastini; Fauna Herawati
Jurnal Sains dan Kesehatan Vol. 3 No. 4 (2021): J. Sains Kes.
Publisher : Fakultas Farmasi, Universitas Mulawarman, Samarinda, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25026/jsk.v3i4.582

Abstract

ABSTRAK Sekitar 80-90% pasien cystic fibrosis akan mengalami pancreatic insuffiency. Keadaan ini akan menyebabkan terjadinya malabsorpsi lemak dan protein dan akan berpengaruh pada status nutrisi dari pasien. Terapi dari terjadinya pancreatic insufficiency ini adalah dengan pemberian pancreatic enzyme replacement therapy (PERT) untuk meningkatkan absorpsi dari lemak dan juga protein pada pasien cystic fibrosis. Tujuan dari kajian sistematis ini adalah untuk mengetahui efikasi dan keamanan dari pemberian terapi PERT pada pasien yang mengalami pancreatic insufficiency pada pasien cystic fibrosis sehingga dapat dijadikan acuan atau pedoman dalam pemberian terapi PERT. Proses penelusuran pustaka melalui PUBMED dan Cohcrane Library menggunakan kata kunci PERT dan Cystic Fibrosis dengan Boolean operator “AND”. Penelitian yang terpilih sebanyak 14 dengan kriteria berupa RCT, pasien segala usia, pasien cystic fibrosis dengan pancreatic insufficiency, dan membandingkan PERT dengan plasebo atau formulasi lain. Dari empat belas penelitian semua studi memperlihatkan peningkatan % CFA dari pemberian terapi PERT. Peningkatan % CFA dari semua studi mencapai rentang > 60% sampai > 80%. Studi yang membandingkan sediaan PERT dengan plasebo menunjukan hasil bahwa PERT mampu meningkatankan % CFA menjadi > 70% sementara plasebo memiliki % CFA sekitar 40% dan pemberian terapi PERT dinilai relatif aman dan dapat ditoleransi oleh pasien dengan cystic fibrosis. ABSTRACT Approximately 80-90% patients with cystic fibrosis will experience pancreatic insufficiency. This condition will cause the malabsorption of fats and proteins and will affect the nutritional status of the patients. Therapy of pancreatic insufficiency is by administering of pancreatic enzyme replacement therapy (PERT) to increase absorption of fat and protein in patients with cystic fibrosis. This systematic review aimed determine the efficacy and safety of the administration of PERT in patients who experience pancreatic insufficiency with cystic fibrosis, and this systematic review can be used as reference or guideline in the administration of PERT. The search strategy was undertaken using PUBMED and Cochrane Library, and the search term were “PERT” and “Cystic Fibrosis” wich were combines with the use of Boolean operator “AND”. In total, 14 studies were include in the final review with criteria is RCT, patients of any age, patients with cystic fibrosis and pancreatic insufficiency, and compared to placebo or other formulations. All studies showed an increase in the % CFA from administration of PERT. the increase of % CFA from all studies reached a range of > 60% to > 80%. Studies comparing PERT and placebo showed that PERT was able to increase of % CFA to > 70% while placebo had % CFA about 40% and PERT therapy was considered relatively safe and well tolerated by patients with cystic fibrosis.
Analysis of antibiotic use in diabetic ulcer patients at a private hospital in Surabaya Fauna Herawati; Nadila Suleman; Rika Yulia; Heru Wijono
Indonesian Journal of Biomedicine and Clinical Sciences Vol 56 No 4 (2024)
Publisher : Published by Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/inajbcs.v56i4.18422

Abstract

Diabetic ulcer is one of the complications of diabetes mellitus in the form of chronic wounds due to neuropathy and peripheral arterial disease. Bacteria enter in a wound and cause a skin infection. Appropriate antibiotic therapy is needed to prevent antibiotic resistance. The purpose of this study was to evaluate the quantity profile of antibiotic use using the prescribed daily dose (PDD) and days of therapy (DOT) methods compared with the therapeutic guidelines (PPAB) in diabetic ulcer patients for the period January 2020 - June 2022 at a private hospital in Surabaya, Indonesia. This observational study with the retrospective data collection using medical records was analysed descriptively. The results showed that the total PDD value was 20.44 g/day. The highest antibiotic prescriptions were ceftriaxone (2.39 g/day) and metronidazole (1.46 g/day), respectively. The total days of therapy was 12.13 DOT; the DOT more than 4.00 were metronidazole (4.15 DOT) and ceftriaxone (4.09 DOT). This study reported a high PDD and DOT that will cause antibiotic resistance in the future.
LAPORAN KASUS: ANALISIS KOMBINASI PENGGUNAAN HEPATOPROTEKTOR PADA CEDERA HATI KARENA INFEKSI BAKTERI STREPTOCOCCUS VIRIDANS Muhammad Hasan Andryanto; Fauna Herawati; Umi Fatmawati
Jurnal Ilmiah Ibnu Sina (JIIS): Ilmu Farmasi dan Kesehatan Vol 9 No 2 (2024): JIIS
Publisher : Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36387/jiis.v9i2.2179

Abstract

Streptococcus viridans is one of the bacteria that can cause Community-Acquired Pneumonia (CAP). CAP disease has a higher prevalence of non-alcohol-related fatty liver disease (NAFLD). Continuous increase in fat levels in the liver triggered by pneumonia can cause inflammation in the liver, it causes a rapid decline in liver function and results in increased levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin. The use of hepatoprotectors in conditions of impaired liver function is essential to improve liver cell regeneration and promote liver detoxification. One of the drugs and supplements that can act as a hepatoprotector is ursodeoxycholic acid (UDCA) and Curcuma. Here we report the use of hepatoprotector drugs in cases of Community-Acquired Pneumonia (CAP) disease due to Streptococcus viridans bacteria in patients without comorbidities with the results of liver function test examinations from the beginning of hospital admission, during treatment, until the patient is discharged. The purpose of our case report is to illustrate the effect of the combined use of UDCA and Curcuma drugs on liver injury due to Streptococcus viridans bacterial infection in order to prevent complications, morbidity, mortality and improve the quality of life of patients. Based on the case reports that we present, the combined use of UDCA and Curcuma drugs as hepatoprotectors can improve liver function with reduced parameters of AST, ALT, and total bilirubin levels.
Co-Authors Abdul Kadir Jaelani Anak Agung Gede Sugianthara Dwi Octamy Sari Erfin Midhiawati Faiz Farikhah Fawandi Fuad Alkindi Ferdias Kurnia Bahari Firmansah, Moh. Heru Wijono Ita Octafia Linda Wahyuni Wongkar Muhammad Hasan Andryanto Muhammad Hasan Wattiheluw Nadila Suleman Ni Made Suastini Nurul Akhirin Nisak Retno Juwita Sari Rika Yulia Rika Yulia Ruddy Hartono Sandra Annisa Setiasih Setiasih Umi Fatmawati